KMT2A and acute myeloid leukemia: Specifically, our findings demonstrate that the combination of SNDX-50469 with BET protein, p300/CBP histone acetyltransferase (HAT), MOZ (KAT6A), or KDM1A (LSD1) inhibitor (LSD1i) exerts synergistic lethal activity against AML cell lines and PD AML cells harboring MLL-FP or NPM1c [23–26].